Valuation : Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Market Cap 4.22B 629M 541M 509M 465M 867M 59.66B 871M 6.03B 2.33B 30.49B 2.36B 2.31B 97.03B P/E 2024
506x
P/E 2025 -55.7x
Enterprise Value 5.23B 779M 670M 630M 575M 1.07B 73.83B 1.08B 7.46B 2.89B 37.74B 2.92B 2.86B 120B EV / Sales 2024
6.63x
EV / Sales 2025 7.43x
Free-Float
37.78%
Yield 2024 *
-
Yield 2025 -
08-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Announces Changes to Its Board CI
04-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
01-14 Bohui Innovation Biotechnology Gets Clinical Trial Approval for Anti-Rabies Human Rabies MT
11-12 Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine MT
29/10/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
27/08/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
02/06/25 Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit MT
28/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
21/02/25 Beijing Bohui Innovation Biotechnology Group Subsidiary Gains Clinical Trial Approval for Flu Vaccine MT
1 day+1.77%
1 week-0.39%
Current month+0.78%
1 month+4.44%
3 months+10.00%
6 months-16.61%
Current year-17.54%
1 week 5
Extreme 5
5.22
1 month 4.81
Extreme 4.81
5.9
Current year 4.06
Extreme 4.06
8.17
1 year 4.06
Extreme 4.06
8.63
3 years 3.43
Extreme 3.43
8.63
5 years 3.43
Extreme 3.43
12.28
10 years 3.43
Extreme 3.43
23.8
Manager TitleAgeSince
Chief Executive Officer 56 17/03/2020
Director of Finance/CFO 42 29/06/2020
Corporate Officer/Principal 48 17/03/2020
Director TitleAgeSince
Chairman 58 19/05/2014
Chairman 48 01/06/2022
Director/Board Member 56 29/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/21 A Sell

Executive/Senior Manager

268,300 0.0364%
9/15/21 A Sell

Executive/Senior Manager

50,000 0.0068%
1/26/21 A Buy

Chairman

29,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+1.77%-0.39%-13.69%-1.34% 629M
-2.10%-1.64%+45.10%-2.45% 80.91B
-0.78%-1.52%-18.45%-36.25% 60.46B
-3.59%-9.04%+465.16%+30.37% 56.02B
-1.77%-5.26%-9.16%+29.36% 49.63B
-1.93%-7.98%-2.97%+146.18% 45.88B
-3.77%-1.64%+50.34%-17.95% 31.4B
-1.85%-0.49%+43.72%+94.44% 25.22B
-2.00%-3.54%-2.68%+156.40% 22.25B
-2.98%-2.51%+60.38%+100.00% 16.59B
Average -1.60%-1.22%+61.78%+49.87% 38.9B
Weighted average by Cap. -1.76%-1.43%+81.29%+37.10%

Financials

2024 2025
Net sales 852M 127M 109M 103M 93.67M 175M 12.03B 176M 1.22B 471M 6.15B 477M 466M 19.57B 825M 123M 106M 99.38M 90.69M 169M 11.65B 170M 1.18B 456M 5.95B 461M 451M 18.94B
Net income 9.25M 1.38M 1.18M 1.11M 1.02M 1.9M 131M 1.91M 13.2M 5.11M 66.75M 5.17M 5.06M 212M -91.92M -13.7M -11.78M -11.08M -10.11M -18.87M -1.3B -18.96M -131M -50.78M -664M -51.43M -50.31M -2.11B
Net Debt 974M 145M 125M 117M 107M 200M 13.76B 201M 1.39B 538M 7.03B 545M 533M 22.38B 1B 150M 129M 121M 110M 206M 14.17B 207M 1.43B 554M 7.24B 561M 549M 23.05B
Logo Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Employees
2,170
Date Price Change Volume
08/09/26 CN¥5.170 +1.77% 7,257,143
07/09/26 CN¥5.080 0.00% 5,462,400
04/09/26 CN¥5.080 +1.20% 9,093,900
03/09/26 CN¥5.020 -1.18% 6,698,300
02/09/26 CN¥5.080 -2.12% 7,233,800
  1. Stock Market
  2. Stocks
  3. 300318 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!